Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation

Tango Therapeutics, Inc.

2022-Q2 EPS reported -$0.57 revenue$11,529,000

Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.
Net loss $24.9M ($0.28/share) vs $4.5M ($0.09) in Q2 2021; R&D expense $23.7M vs $19.1M.
TNG908 Phase 1/2 enrolling MTAP-deleted solid tumors; FDA Orphan Drug Designation for MPNST.
TNG462 (45-fold more potent PRMT5 inhibitor) and TNG260 declared development candidates; IND filings expected 1H 2023.
Added to Russell 2000, 3000 and Microcap indexes in June 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.